Patent Bill Aims For Trolls, But Will It Snare Rx Firms Instead?
Rep. Bob Goodlatte’s Innovation Act would delay discovery, require more information to file suits, which could increase the time and expense of pursuing infringement cases.
You may also be interested in...
“One-size-fits-all” patent troll bill will harm innovators, Johnson & Johnson’s chief IP counsel tells Senate hearing.
Amendments make things a little better for drug firms as attention now shifts to the Senate version.
Apotex’s challenge of Alcon’s Vigamox patent put PTO’s new inter partes review proceeding in the spotlight; 45 petitions have been filed in the biopharma sector.